Figures computed from official regulatory filings — .
Analysttarget 36.75 USD (+89%) · consensus 4.82/5 · 17 buy · 0 hold · 0 sell
Ownershipinsiders 0.17% · institutions 126.76% · short 17.8% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Viridian Therapeutics, Inc.\DE only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves' disease and TED. Its portfolio of engineered inhibitors of the neonatal Fc receptor (FcFn) includes VRDN-006, a highly selective Fc fragment, and VRDN-008, a half-life extended bispecific FcRn inhibitor comprising an GC fragment and an albumin-binding domain designed to prolong IGG suppression. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was incorporated in 2010 and is headquartered in Waltham, Massachusetts.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
13 buys32 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| Tousignant Jennifer | Sell | $103.2K | SEC |
| Tousignant Jennifer | Sell | $245K | SEC |
| Tousignant Jennifer | Exercise | $144.1K | SEC |
| Tousignant Jennifer | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Tripuraneni Radhika | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Tripuraneni Radhika | Exercise | $528.4K | SEC |
| Gheuens Sarah | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Kiselak Tomas | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Moses Jennifer K. | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Morris Arlenetrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| CAIN CHRISTOPHER W. | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Ajer Jeffrey Robert | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Fairmount Funds Management LLCtrack record | Buy | $20M | conv 45 | SEC |
| Tousignant Jennifer | Other | $50.6K | SEC |
| Mahoney Stephen F. | Other | $223.6K | SEC |
| Harmon Seth | Other | $61.3K | SEC |
| Beetham Thomas W. | Other | $92K | SEC |
| Beetham Thomas W. | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Mahoney Stephen F. | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Beetham Thomas W. | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Tousignant Jennifer | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Mahoney Stephen F. | Exercise | n/a (No price was disclosed in the filing) | SEC |
| Harmon Seth | Exercise | n/a (No price was disclosed in the filing) | SEC |
| Harmon Seth | Other | $61.3K | SEC |
| Tousignant Jennifer | Other | $50.5K | SEC |